Plain-English translation of NCT04685317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Atrial fibrillation ablation is a procedure that helps correct an irregular heartbeat. During this procedure, tiny debris can sometimes travel to the brain and cause stroke or thinking problems. This trial is testing whether the Sentinel® Cerebral Protection System—a small device placed in your heart during the ablation—can catch this debris and protect your brain from harm.
Atrial fibrillation ablation is an effective treatment, but there's a small risk that debris created during the procedure could reach the brain. This trial exists to see whether using a protective device during ablation can reduce that risk and keep your brain safer.
You likely qualify if…
You likely don't qualify if…
If you're selected for this trial, you'll undergo your ablation procedure as planned, and the protective device will be placed in your heart at the start and removed at the end. After the procedure, the study team will call you 30 days later to check on you. At 90 days, you'll return for a final visit that includes a 30-minute thinking and memory test. Some participants will receive the protective device, while others will have standard ablation care without it.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States
Sponsor
Malini Madhavan
Enrollment target
~48 participants
Started
March 2023
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Joseph Abdel Messih
Mayo Clinic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.